Advertisement

Pharmacy World & Science

, Volume 32, Issue 3, pp 334–338 | Cite as

Views of parents and pharmacists following participation in a paediatric pharmacovigilance study

  • Mansour Tobaiqy
  • Derek Stewart
  • Peter J. Helms
  • Christine M. Bond
  • Amanda Jane Lee
  • James McLayEmail author
Short Research Report

Abstract

Objective To explore the experiences and views of community pharmacists and parents participating in a prospective paediatric pharmacovigilance study. Method Twenty-five pharmacists and 32 parents were approached for telephone interview. Interviews were audio-recorded, transcribed and analysed thematically to identify recurring issues and themes. Results Seventeen pharmacists and 22 parents were interviewed. Parents and pharmacists agreed that more information about the side effects of medicines in children was required. Both groups reported willingness to participate in future prospective pharmacovigilance studies, although pharmacists expressed concerns about the lack of financial incentives. Pharmacists reported that parents had concerns regarding the confidentiality of their child’s ADR data and the study data collection process. Conclusion This study highlighted positive and negative opinions of parents and pharmacists regarding their experiences in this research project. Maintaining confidentiality in relation to indication and medicines prescribed were important issues for parents whereas time constraints and lack of financial incentives were key issues influencing participation by community pharmacists.

Keywords

Adverse drug reactions Community pharmacists Experiences Parents Pharmacovigilance Scotland Telephone interviews Views 

Notes

Acknowledgment

We would like to thank all the parents and community pharmacists who took part in this research and administration staff at Aberdeen University.

Funding

We acknowledge funding provided by the Scottish Chief Scientist’s Office (CSO).

Conflicts of interest

There were no conflicts of interest.

References

  1. 1.
    BMA. Reporting adverse drug reactions—a BMA policy document. BMA, London. 1996. http://www.bma.org.uk/images/ADRFinal_tcm41-20713.pdf. Accessed 22 Dec 2009.
  2. 2.
    Choonara I. Direct reporting of suspected adverse drug reactions by patients. J R Soc Med. 2004;97:316–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994. J R Coll Phys Lond. 1995;29(1):41–9.Google Scholar
  4. 4.
    Belton KJ, Lewis SC, Payne S, Rawlins MD, Wood SM. Attitudinal survey of ADR reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol. 1995;39:223–6.PubMedGoogle Scholar
  5. 5.
    Carleton BC, Smith MA, Gelin MN, Heathcote SC. Paediatric adverse drug reaction reporting: understanding and future directions. Can J Clin Pharmacol. 2006;14(1):45–57.Google Scholar
  6. 6.
    McLay JS, Tanaka M, Ekins-Daukes S, Helms PJ. A prospective questionnaire assessment of attitudes and experiences of off label prescribing amongst hospital based paediatricians. Arch Dis Child. 2006;91:584–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Cox A. Embracing ADR reporting could improve pharmacists’ standing. Pharm J. 2002;269:14.Google Scholar
  8. 8.
    Tobaiqy M, Bond C, Helms P, Lee A, Stewart D, McCaig D, Bateman N A, McLay JS. A pilot study to evaluate a community pharmacy based monitoring system to identify adverse drug reactions associated with paediatric medicines use. Eu J Clin Pharm. 2010. doi: 10.1007/s00228-010-0790-9.
  9. 9.
    Stewart D, Helms P, McCaig D, Bond C, McLay J. Monitoring adverse drug reactions in children using community pharmacies: a pilot study. Br J Clin Pharm. 2005;59(6):677–83.CrossRefGoogle Scholar
  10. 10.
    Marshall MN. Sampling for qualitative research. Fam Pract. 1996;13:522–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Armour C, Brillant M, Krass I. Pharmacists’ views on involvement in pharmacy practice research: strategies for facilitating participation. Pharm Pract. 2007;5(2):59–66.Google Scholar
  12. 12.
    Adrianne F, de Jong-van den Berg LTW, Netjes K, et al. Recruitment of parents and physicians of stimulant-using children via community pharmacies is successful. J Clin Epidemiol. 2005;58:1072–3.CrossRefGoogle Scholar
  13. 13.
    Alvarez-Requejo A, Carvalja A, Bégaud B, Moride Y, Verga T, Martín Arias LH. Underreporting of adverse drug reactions—estimate based on a spontaneous reporting schema and a sentinel system. Eur J Clin Pharmacol. 1998;54:483–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Dickerson FB, Sommerville J, Origoni AE, Ringel NB, Parente F. Experiences of stigma among outpatients with schizophrenia. Schizophr Bull. 2002;28:143–55.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Mansour Tobaiqy
    • 1
  • Derek Stewart
    • 2
  • Peter J. Helms
    • 1
  • Christine M. Bond
    • 3
  • Amanda Jane Lee
    • 3
  • James McLay
    • 1
    Email author
  1. 1.Division of Applied Health Sciences, The Aberdeen Medical SchoolThe University of AberdeenAberdeenScotland, UK
  2. 2.School of Pharmacy and Life SciencesRobert Gordon UniversityAberdeenScotland, UK
  3. 3.Centre of Academic Primary Care, The Aberdeen Medical SchoolThe University of AberdeenAberdeenUK

Personalised recommendations